PCSK9 Inhibitors (Evolocumab, Inclisiran) vs Statins (Atorvastatin/Rosuvastatin)
Both are used for cardiovascular. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| PCSK9 Inhibitors (Evolocumab, Inclisiran) | Statins (Atorvastatin/Rosuvastatin) | |
|---|---|---|
| Human evidence | ★★★★★ | ★★★★★ |
| Legal status | FDA Approved | FDA Approved |
| How it works | Block PCSK9, the protein that degrades LDL receptors — so LDL receptors survive longer and clear far more LDL. Inclisiran is an siRNA silencing PCSK9, dosed twice yearly. | Inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of cholesterol synthesis → upregulated LDL receptors clear LDL from blood; also anti-inflammatory (lower CRP). |
| In plain English | LDL receptors are the vacuum cleaners that remove bad cholesterol; PCSK9 destroys them. Block PCSK9 and the vacuums keep working — dropping LDL dramatically. Inclisiran is a gene-silencing shot given just twice a year. | Turn down your liver's cholesterol factory so it pulls LDL out of your blood instead. The most evidence-backed drugs for preventing heart attacks. Pair with CoQ10 (statins deplete it). |
| Bottom line | Most powerful LDL-lowering available; the siRNA form is a genuine leap. | Cornerstone of cardiovascular prevention. |
| Availability | Available over the counter | Available over the counter |
Which is better for cardiovascular?
Both carry a comparable human-evidence rating (★★★★★). Choose on mechanism fit, side-effects, availability and cost rather than evidence strength alone — they work through different mechanisms.
Full breakdowns: PCSK9 Inhibitors (Evolocumab, Inclisiran) · Statins (Atorvastatin/Rosuvastatin).
Common questions
Is PCSK9 Inhibitors (Evolocumab, Inclisiran) or Statins (Atorvastatin/Rosuvastatin) better for cardiovascular?
Both carry a comparable human-evidence rating (★★★★★). Choose on mechanism fit, side-effects, availability and cost rather than evidence strength alone — they work through different mechanisms.
What's the difference between PCSK9 Inhibitors (Evolocumab, Inclisiran) and Statins (Atorvastatin/Rosuvastatin)?
PCSK9 Inhibitors (Evolocumab, Inclisiran): Most powerful LDL-lowering available; the siRNA form is a genuine leap. — Statins (Atorvastatin/Rosuvastatin): Cornerstone of cardiovascular prevention.